Pipeline

PBF-677

Potent and selective, GI-restricted adenosine A3 receptor antagonist as first in class oral treatment for IBD. Phase I in healthy volunteers and a POC trial in ulcerative colitis patients have been completed.

PBF-1129

Potent and selective adenosine A2b receptor antagonist as first in class oral treatment for Idiopathic Pulmonary Fibrosis and lung cancer. Phase I clinical trials in healthy volunteers have been completed with the compound and a Phase I dose escalation study in lung cancer patients is in progress.

PBF-1650

Potent and selective, orally bioavailable adenosine A3 receptor antagonist for the treatment of autoimmune diseases like psoriasis and atopic dermatitis. Phase I studies in healthy volunteers have been completed.

PBF-680

Potent, non-BBB permeable, adenosine A1 receptor antagonist as a first in class oral treatment of respiratory diseases as asthma and COPD. The compound has demonstrated excellent safety, tolerability, and pharmacokinetic profile in humans following administration of single and multiple ascending doses. A Phase II trial in asthmatics has been completed with positive results. A Phase II clinical trial in moderate to severe COPD patients is in progress.

PBF-999

Novel Phosphodiesterase 10 (PDE-10) inhibitor for the treatment of metabolic diseases. A phase II trial in Prader Willi syndrome patients is in progress.

PBF-509

Potent, non-furan containing adenosine A2A receptor antagonist for as novel checkpoint inhibitor for the treatment of solid tumors. The compound has been out-licensed to Novartis through an agreement signed in 2015.